(Q27824815)

English

The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase.

scientific article

Statements

The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase (English)

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit